Connect your AI

Tango Therapeutics TNGX Temporary Equity Shares Outstanding

Temporary Equity Shares Outstanding at other companies

BillionToOne, Inc. BLLN

0-100%

Other financials

Income statement

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

Market cap$4.55B+1,915%

Enterprise value$4.43B+2,204%

P/S79.9×+74.4×

Profitability

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:TemporaryEquitySharesOutstanding.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's temporary equity shares outstanding.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Tango Therapeutics's temporary equity shares outstanding?: Tango Therapeutics (TNGX) reported temporary equity shares outstanding of 0 in Q1 2026.